NRIX Valuation

Nurix Therapeutics Inc

Add to Watchlist

Advanced Chart

9.340

-0.07(-0.744%)1D

Overview
Forecast
Valuation
Earnings

NRIX Relative Valuation

NRIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NRIX is overvalued; if below, it's undervalued.

Historical Valuation

Nurix Therapeutics Inc (NRIX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.87 is considered Undervalued compared with the five-year average of -6.63. The fair price of Nurix Therapeutics Inc (NRIX) is between 22.54 to 38.62 according to relative valuation methord. Compared to the current price of 9.41 USD , Nurix Therapeutics Inc is Undervalued By 58.25%.

Relative Value

Fair Zone

22.54-38.62

Current Price：9.41

58.25%

Undervalued

-2.65

Trailing

Forward

-1.07

EV/EBITDA

Nurix Therapeutics Inc. (NRIX) has a current EV/EBITDA of -1.07. The 5-year average EV/EBITDA is -4.41. The thresholds are as follows: Strongly Undervalued below -13.18, Undervalued between -13.18 and -8.79, Fairly Valued between -0.02 and -8.79, Overvalued between -0.02 and 4.36, and Strongly Overvalued above 4.36. The current Forward EV/EBITDA of -1.07 falls within the Historic Trend Line -Fairly Valued range.

-0.89

EV/EBIT

Nurix Therapeutics Inc. (NRIX) has a current EV/EBIT of -0.89. The 5-year average EV/EBIT is -3.99. The thresholds are as follows: Strongly Undervalued below -11.51, Undervalued between -11.51 and -7.75, Fairly Valued between -0.22 and -7.75, Overvalued between -0.22 and 3.54, and Strongly Overvalued above 3.54. The current Forward EV/EBIT of -0.89 falls within the Historic Trend Line -Fairly Valued range.

11.70

Nurix Therapeutics Inc. (NRIX) has a current PS of 11.70. The 5-year average PS is 19.39. The thresholds are as follows: Strongly Undervalued below -5.97, Undervalued between -5.97 and 6.71, Fairly Valued between 32.07 and 6.71, Overvalued between 32.07 and 44.75, and Strongly Overvalued above 44.75. The current Forward PS of 11.70 falls within the Historic Trend Line -Fairly Valued range.

-3.22

P/OCF

Nurix Therapeutics Inc. (NRIX) has a current P/OCF of -3.22. The 5-year average P/OCF is -8.45. The thresholds are as follows: Strongly Undervalued below -24.51, Undervalued between -24.51 and -16.48, Fairly Valued between -0.42 and -16.48, Overvalued between -0.42 and 7.61, and Strongly Overvalued above 7.61. The current Forward P/OCF of -3.22 falls within the Historic Trend Line -Fairly Valued range.

-2.86

P/FCF

Nurix Therapeutics Inc. (NRIX) has a current P/FCF of -2.86. The 5-year average P/FCF is -6.73. The thresholds are as follows: Strongly Undervalued below -17.37, Undervalued between -17.37 and -12.05, Fairly Valued between -1.42 and -12.05, Overvalued between -1.42 and 3.90, and Strongly Overvalued above 3.90. The current Forward P/FCF of -2.86 falls within the Historic Trend Line -Fairly Valued range.

Nurix Therapeutics Inc (NRIX) has a current Price-to-Book (P/B) ratio of 1.61. Compared to its 3-year average P/B ratio of 2.44 , the current P/B ratio is approximately -34.11% higher. Relative to its 5-year average P/B ratio of 2.87, the current P/B ratio is about -43.93% higher. Nurix Therapeutics Inc (NRIX) has a Forward Free Cash Flow (FCF) yield of approximately -30.93%. Compared to its 3-year average FCF yield of -24.14%, the current FCF yield is approximately 28.13% lower. Relative to its 5-year average FCF yield of -17.96% , the current FCF yield is about 72.15% lower.

1.61

P/B

Median3y

2.44

Median5y

2.87

-31.39

FCF Yield

Median3y

-24.14

Median5y

-17.96

Competitors Valuation Multiple

The average P/S ratio for NRIX's competitors is 100.85, providing a benchmark for relative valuation. Nurix Therapeutics Inc Corp (NRIX) exhibits a P/S ratio of 11.70, which is -88.40% above the industry average. Given its robust revenue growth of 264.34%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NRIX.O

Nurix Therapeutics Inc

Dianthus Therapeutics Inc

Tango Therapeutics Inc

Taysha Gene Therapies Inc

Anavex Life Sciences Corp

Performance Decomposition

Market capitalization of NRIX decreased by 62.66% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 12.09M to 44.06M.

The secondary factor is the Margin Expansion, contributed -73.22%to the performance.

Overall, the performance of NRIX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

264.34%

12.09M → 44.06M

Revenue Growth

-73.22%

-368.39 → -98.66

Margin Expansion

-253.78%

2.35 → -3.62

P/E Change

-62.66%